Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07040566 · ClinicalTrials.gov registry record · Phase 2
A Trial of Varenicline for E-cigarette Cessation
A Phase 2 study of Nicotine Dependence and Vaping, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
- 2
- Study locations
NCT07040566: Recruiting Phase 2 study of Nicotine Dependence and Vaping, sponsored by Yale University.
NCT07040566 is a Phase 2 study of Nicotine Dependence and Vaping that is actively recruiting participants, run by Yale University. The registered enrollment target is 326 participants, above the 182-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (79% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07040566, a Phase 2 study of Nicotine Dependence and Vaping, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
Primary Outcome
7-day point-prevalence e-cigarette abstinence (PPA) at Week 12 defined as no ecigarette use \[and no use of any combusted tobacco product\], not even a puff, biochemically verified by saliva cotinine
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline 1mg BID
Study Locations (2)
Connecticut
- Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven - New Haven
South Carolina
- Hollings Cancer Center at MUSC (HCC) - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 2 |
What NCT07040566 shows while recruiting
NCT07040566 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, above the 182-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (79% higher).
The record links to 3 conditions, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07040566 reports a single indexed study location in Connecticut, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07040566 about?
NCT07040566 is a clinical study titled "A Trial of Varenicline for E-cigarette Cessation". This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
What is the current status of trial NCT07040566?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2025-10-14. Estimated completion is 2030-10-30.
What conditions does trial NCT07040566 study?
This clinical trial studies the following conditions: Nicotine Dependence, Vaping, E-cigarette Use.
What interventions are being tested in trial NCT07040566?
The interventions under investigation include: Placebo (DRUG), Varenicline 1mg BID (DRUG).
Who is sponsoring clinical trial NCT07040566?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07040566 being conducted?
This trial has 2 study locations across Connecticut, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07040566's enrollment target sits among peer trials
326 12th of 67 higher than 56 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI